Sector News

Bellicum buys into CAR-T manufacturing amid a hot immuno-oncology race

May 8, 2015
Life sciences
Following the lead of Juno Therapeutics and Kite Pharma, CAR-T contender Bellicum Pharmaceuticals ($BLCM) is splashing cash on an in-house manufacturing operation, speeding its cell therapies into clinical trials in a host of cancers.
 
The biotech has leased a 27,000-square-foot manufacturing site that can churn out the modified T cells needed for so-called CAR-T therapies, which soup up patients’ immune systems to fight cancer. The new facility will sit on Bellicum’s Houston campus, adjacent to the Texas Medical Center, the company said.
 
CAR-T rivals Juno and Kite each made similar splashes on manufacturing this year, believing that the complex process of crafting cell therapies is best done internally and not left to contractors. Novartis, a leader in the space, has built dedicated facilities of its own, and each company is pursuing a fleet of clinical trials in hopes of establishing CAR-T’s promise in more and more indications.
 
“Bringing manufacturing in-house allows us to build upon our process and assay development expertise and streamline the production of our cell therapy product candidates, under our full control,” Bellicum CEO Tom Farrell said in a statement. “The planned facility is intended to provide study drug for clinical studies of BPX-501 and to support the development of our expanding pipeline of TCR and CAR-T adoptive cell therapy product candidates.”
 
BPX-501, a T cell therapy designed to ward off graft-versus-host disease in patients undergoing stem cell transplants, is Bellicum’s most advance asset, and the company has applied the same technology to oncology. Bellicum’s cancer pipeline includes BPX-401, a CAR-T candidate targeting the CD19 antigen, which is expressed by hematological cancer cells. Following that is BPX-601, another CAR-T that targets solid tumors, and BPX-701, an immunotherapy for skin cancer.
 
Each of the company’s cell therapies is equipped with a “safety switch” Bellicum says can mute unwanted transplant reactions like cytokine release syndrome, a common response to CAR-T therapy that has occasionally proven fatal in early studies. That feature, the company is betting, will help its assets stand out in a fast-crowding field.
 
By Damian Garde
 

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend